{"nctId":"NCT01045447","briefTitle":"Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2010-01"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":465,"armGroups":[{"label":"IDegAsp OD","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec/insulin aspart"]},{"label":"IGlar OD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin glargine"]}],"interventions":[{"name":"insulin degludec/insulin aspart","otherNames":[]},{"name":"insulin glargine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months\n* Treatment with basal insulin regimen (insulin detemir, insulin glargine or neutral protamine Hagedorn \\[NPH\\] insulin) once daily (OD), for at least 3 months\n* Ongoing treatment with: metformin with or without other oral antidiabetic drugs (OADs) for at least 3 months prior to randomisation\n* HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis\n* BMI maximum 40.0 kg/m\\^2\n\nExclusion Criteria:\n\n* Treatment with insulin regimens other than a basal insulin regimen (insulin detemir or insulin glargine or NPH insulin) OD within 3 months prior to Visit 1\n* Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists within 3 months prior to visit 1\n* Current rosiglitazone users\n* Cardiovascular disease, within the last 6 months prior to visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty\n* Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)\n* Impaired liver function, defined as alanine aminotransferase (ALAT) at least 2.5 times upper limit of normal (one retest analysed at the central laboratory within a week of receipt of the result is permitted with the result of the last sample being conclusive)\n* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements\n* Cancer and medical history of cancer hereof (except basal cell skin cancer or squamous cell skin cancer)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycosylated Haemoglobin (HbA1c)","description":"Change from baseline in HbA1c after 26 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.98","spread":"1.01"},{"groupId":"OG001","value":"-1.00","spread":"1.06"}]}]}]},{"type":"SECONDARY","title":"Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)","description":"Mean of SMPG after 26 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am and before breakfast.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"2.0"},{"groupId":"OG001","value":"8.4","spread":"2.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":230},"commonTop":["Headache","Nasopharyngitis","Diarrhoea","Upper respiratory tract infection","Oedema peripheral"]}}}